To study efficacy and tolerability of alirocumab in Austrian clinical practice
Latest Information Update: 23 Jun 2021
At a glance
- Drugs Alirocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Acronyms PEARL-AT
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 23 Jun 2021 New trial record